Incorporated in 1983, Dishman Carbogen Amcis Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, the company is a leading global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up, and manufacturing services.

The company aids drug innovators for development and process optimization for novel drug molecules in various stages of the development process. Once the innovative molecules are approved, the company further explore the possibility of large scale commercial supply tie-ups. The company is generating a healthy pipeline of contract manufacturing opportunities commensurate to the growing revenue base of manufacturing. Its robust business model is capable of sustaining growth, with CRAMS being the focal point of all its strategic efforts.

Business area of the company

The company is a fully integrated CRAMS player working with global pharmaceutical innovators. It has a global presence with development and manufacturing facilities across Europe, India, and China. It provides end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.

Dishman Carbogen Amcis Ltd.

IOL Chemicals And Pharmaceuticals Ltd.

RPG Life Sciences Ltd.

Morepen Laboratories Ltd.

Supriya Lifescience Ltd.

Unichem Laboratories Ltd.

Alembic Ltd.

Gufic Biosciences Ltd.

Orchid Pharma Ltd.

Sequent Scientific Ltd.

Shilpa Medicare Ltd.

TTK Healthcare Ltd.

Suven Life Sciences Ltd.

Amrutanjan Health Care Ltd.

Indoco Remedies Ltd.

Market Cap	2,559 Cr	ROE	-0.5%
P/E Ratio(TTM)	0.0	EPS(TTM)	0.0
P/B Ratio	0.4	Dividend Yield	0.0%
Industry P/E	40.7	Book Value	368.1
		Face Value	2.0

Fundamentals